- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03370458
Lactobacillus Plantarum DR7 for Gut-Brain-Axis Benefits (DR7)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Probiotics are "live microorganisms which, when administered in adequate amounts, can confer health benefits on the host". Probiotics, which beneficially affect the host by improving the intestinal microbial balance, may affect the immune response, thus boosting the body system to combat against diseases. While numerous microorganisms that may confer health benefits to the host, the most widely studied probiotics are from the Lactobacillus genera. For the past few decades, probiotics have been studied extensively for their beneficial effects mainly on the host's guts. Recently, probiotics are studied for their promising potentials along the gut-brain-axis. The 'gut-brain-axis' is a bidirectional communication system, dynamic for maintaining homeostasis. Many studies show that certain strains of Lactobacillus improved human's health such as reducing the occurrence of diarrhea caused by rotavirus infections, antibiotic treatment, chemotherapy, or lactose intolerance, reduced irritable bowel syndrome symptoms and treating atopic diseases. Lactobacillus have also gained increasing evidences as an effective therapy in preventing respiratory tract infections such as sinusitis, bronchitis and pneumonia. While the precise mechanisms of using Lactobacillus in management of respiratory infections are largely unknown, speculations include: Lactobacillus compete against pathogens; increase the barrier function in respiratory epithelium; immunostimulatory effects by enhancing cellular immunity with increased activity of natural killer cells and macrophages in airways. Lactobacilli, as one of the largest genera for probiotic microorganisms have been researched to alleviate stress, anxiety and/or depression disorders.
Lactobacillus plantarum DR7 was isolated from fresh cow's milk in Penang, Malaysia. In-vitro evaluation has shown that this putative probiotic strain adhere to the criteria of probiotic characteristics; a) resistant towards acid and bile conditions of the upper gastrointestinal tract, b) does not possess antibiotic resistance as per requirement of the European Food Safety Authority (EFSA), c) able to adhere to mucin, d) has antioxidant properties, e) able to utilize prebiotics such as fructooligosaccharide (FOS), inulin and galactooligosaccharide (GOS), e) has a carbon metabolism profile adhering to the general patterns of lactobacilli, and f) possess antimicrobial properties against gastrointestinal pathogens. In-vivo evaluation using rats shown that this putative probiotic strain has gut protection properties; a) modulation of gastrointestinal microbial profile via suppressing gut pathogen populations and increasing the population of lactobacilli, b) decreasing pro-inflammatory cytokines and increasing anti-inflammatory cytokines in the plasma, and c) reducing inflammation in the lower intestines.
All these indicated that Lactobacillus plantarum DR7 has the potential to be an effective probiotic strain that modulate gut health and immunity. In addition, due to the alleviation of gastrointestinal stress, this strain may be beneficial along the gut-brain-axis to promote brain health as well.
Lactobacillus plantarum DR7 and placebo are produced under GMP and HALAL certified manufacturing facility. Probiotic Lactobacillus plantarum DR7 appears as light yellow powder. Sachets are stored away from direct sunlight and in below 30C according to the storage condition recommendations of the manufacturer. Each dose was supplied in an aluminium sachet and all sachets are identical in taste and appearance. Probiotic Lactobacillus plantarum DR7 does not contain any porcine or bovine ingredients.
The product contains Lactobacillus plantarum DR7 and maltodextrin as excipient while placebo contains only maltodextrin.
A total number of 124 healthy adults from age 18 -60 years old will be recruited for this study.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Penang
-
Pulau Pinang, Penang, Malaysia, 11800
- School of Industrial Technology, Universiti Sains Malaysia
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female subjects
- 18-60 years old
- Willing to commit throughout the experiment
- Have moderate stress and beyond, as per determined by PSS test
Exclusion Criteria:
- Type-1 diabetes (one of the main metabolite of Lactobacillus is acetic acid. Acetic acid has been reported to affect lipid metabolism in the liver and fat digestion in the pancreas in animal studies, and has been applied in obesity studies)
- Long term medication due to certain severe illness (certain medications may interfere with the survivability of Lactobacillus in the gut, for example the interactions between probiotics and warfarin
- HIV/AIDS (there has been no substantial data on the detrimental effects of probiotics on AIDS patients. However, AIDS patient may be immune-compromised in the sense of "leaky gut" that may lead to bacterial translocation, including translocation of Lactobacillus outside the gut environment, into the blood stream)
- Glucose-6-phosphate dehydrogenase (G6PD) deficiency (there has been no substantial data on the detrimental effects of probiotics on G6PD deficiency people. However, certain strains of probiotics have been reported to benefit RBC irregularity disorders such as spur cells formation. One of the main mechanisms, involve the alteration of RBC membrane. Although this is a benefit, we are unsure of the effects on G6PD deficiency people, with weaker RBC).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Lactobacillus plantarum DR7
Intervention consists of daily administration of 2g probiotic Lactobacillus plantarum DR7, administered daily at a fixed dosage of 9 log CFU/sachet/day and continue for 12 weeks. Intervention: Dietary Supplement: Lactobacillus plantarum DR7 |
This project aims to study the benefits of probiotics namely Lactobacillus plantarum DR7 for brain health benefits primarily to alleviate stress, among adults in Malaysia aged from 18-60 years.
Secondary emphases include respiratory and gastrointestinal health
Other Names:
|
Placebo Comparator: Placebo
Intervention consists of daily administration of 2g placebo (no probiotic bacteria), administered daily and continue for 12 weeks. Intervention: Dietary Supplement: Placebo |
This project aims to study the benefits of probiotics namely Lactobacillus plantarum DR7 for brain health benefits primarily to alleviate stress, among adults in Malaysia aged from 18-60 years.
Secondary emphases include respiratory and gastrointestinal health
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Alleviation of stress
Time Frame: 12 weeks
|
To evaluate the potential of oral administration of Lactobacillus plantarum DR7 in alleviation of stress using PSS questionnaire
|
12 weeks
|
Alleviation of depression
Time Frame: 12 weeks
|
To evaluate the potential of oral administration of Lactobacillus plantarum DR7 in alleviation of depression using DASS42 questionnaire
|
12 weeks
|
Enhancement of cognition ability
Time Frame: 12 weeks
|
To evaluate the potential of oral administration of Lactobacillus plantarum DR7 in enhancing cognition ability using Cogstate Brief Battery
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Alleviation of respiratory tract infections
Time Frame: 12 weeks
|
To evaluate the potential of oral administration of Lactobacillus plantarum DR7 in reducing upper respiratory episodes and symptoms using illness symptom chart
|
12 weeks
|
Alleviation of gastrointestinal disorders
Time Frame: 12 weeks
|
To evaluate the potential of oral administration of Lactobacillus plantarum DR7 in reducing diarrhea incidents using illness symptom chart
|
12 weeks
|
Enhancement of immunity
Time Frame: 12 weeks
|
To evaluate the potential of oral administration of Lactobacillus plantarum DR7 in enhancing immunity via blood cytokines analyses
|
12 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: MT Liong, PhD, Universiti Sains Malaysia
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- USM/JEPeM/17040228
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stress
-
Massachusetts General HospitalCompletedStress | Emotional Stress | Psychological Stress | Social Stress | Life StressUnited States
-
University of PadovaRecruitingStress | Stress Disorder | Work Related StressItaly
-
University of California, Los AngelesUniversity of California, San Francisco; Stanford University; California Initiative...Enrolling by invitationStress | Stress, Psychological | Stress, Emotional | Stress, Physiological | Stress ReactionUnited States
-
Duquesne UniversityUniversity of California, San Diego; West Penn Allegheny Health System; El Centro... and other collaboratorsTerminated
-
University of Sao PauloCompleted
-
Dana-Farber Cancer InstituteEnrolling by invitationStress | Post Traumatic Stress Disorder | Work Related StressUnited States
-
Syracuse VA Medical CenterUS Department of Veterans AffairsCompletedEmotional Stress | Psychological Stress | Life StressUnited States
-
Royal Cornwall Hospitals TrustEnrolling by invitationStress | Stress, Psychological | Stress, JobUnited Kingdom
-
Northumbria UniversityVolac International LtdRecruitingStress | Mood | Physiological StressUnited Kingdom
-
Taichung Veterans General HospitalUnknown
Clinical Trials on Lactobacillus plantarum DR7
-
Region SkaneLund UniversityTerminatedClostridium Difficile Colonisation | Impact of Enteral Probiotics on Certain Lab ParametersSweden
-
National Taiwan University HospitalUnknownRett Syndrome | Tourette Syndrome | Tic DisordersTaiwan
-
Nanfang Hospital of Southern Medical UniversityNot yet recruitingHelicobacter Pylori Infection
-
National Taiwan Sport UniversitySYNBIO TECH INC.CompletedFrail Elderly Syndrome | SarcopeniaTaiwan
-
Region SkaneLund UniversityCompletedOropharyngeal MicrobiologySweden
-
University of CopenhagenThe Ministry of Science, Technology and Innovation, DenmarkCompleted
-
Norwegian University of Science and TechnologySykehuset Innlandet HF; Norwegian Foundation for Health and Rehabilitation; Norwegian... and other collaboratorsCompletedIrritable Bowel Syndrome | Functional Gastrointestinal DisordersNorway
-
Green Cross WellbeingRecruitingRespiratory SymptomsKorea, Republic of
-
Children's Oncology GroupNational Cancer Institute (NCI)Active, not recruitingLymphoma | Leukemia | Hematopoietic and Lymphoid System NeoplasmUnited States, Canada
-
Fakultas Kedokteran Universitas IndonesiaUnited States Agency for International Development (USAID)CompletedConstipation - FunctionalIndonesia